Cargando…

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly

BACKGROUND: Long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in acromegaly. This patient-reported outcomes survey was designed to assess the impact of chronic injections on subjects with acromegaly. METHODS: The survey was conducted in nine pituita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strasburger, Christian J, Karavitaki, Niki, Störmann, Sylvère, Trainer, Peter J, Kreitschmann-Andermahr, Ilonka, Droste, Michael, Korbonits, Márta, Feldmann, Berit, Zopf, Kathrin, Sanderson, Violet Fazal, Schwicker, David, Gelbaum, Dana, Haviv, Asi, Bidlingmaier, Martin, Biermasz, Nienke R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722610/ https://www.ncbi.nlm.nih.gov/pubmed/26744896 http://dx.doi.org/10.1530/EJE-15-1042

Ejemplares similares

Delving into Acromegaly
por: Störmann, Sylvère, et al.
Publicado: (2023)

MON-452 Development of Concepts for Improved Patient Care: What Do Patients with Acromegaly Expect from Their Caregivers?
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2019)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Let’s focus more on regional diversity of acromegaly
por: Störmann, Sylvère
Publicado: (2022)

Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol)
por: Schnabel, Dirk, et al.
Publicado: (2023)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice
por: Geer, Eliza B., et al.
Publicado: (2020)

Motivation for and adherence to growth hormone replacement therapy in adults with hypopituitarism: the patients‘ perspective
por: Kreitschmann-Andermahr, Ilonka, et al.
Publicado: (2020)

Glucocorticoid replacement therapy for primary and secondary adrenal insufficiency and their impact on cognition
por: Harbeck, Birgit, et al.
Publicado: (2023)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

Adults’ Adherence to Growth Hormone Replacement in Relation to Medication-Related Beliefs, Coping and Quality of Life - An Exploratory Analysis
por: Siegel, Sonja, et al.
Publicado: (2021)

SUN-LB078 Biochemically Controlled Acromegaly Patients on a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice Still Remain Symptomatic: Preliminary Results from Endocrinology Health Care Professionals
por: Geer, Eliza, et al.
Publicado: (2019)

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2023)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

SUN-LB077 Relationship between Responses from Acromegaly Patients Treated with a Stable Dose of Injectable Somatostatin Analogues in Routine Clinical Practice and Their Endocrinology Health Care Professional Regarding Treatment Outcomes: Preliminary Findings
por: Geer, Eliza, et al.
Publicado: (2019)

Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
por: Geer, Eliza B., et al.
Publicado: (2019)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Editorial: New Insights and Controversies in Diagnosis and Treatment of Adult Growth Hormone Deficiency
por: Mancini, Antonio, et al.
Publicado: (2022)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial
por: Elenkova, Atanaska, et al.
Publicado: (2022)

OR23-07 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study of Oral Octreotide Capsules in Adult Patients with Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly
por: Samson, Susan, et al.
Publicado: (2022)

Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?
por: Petersenn, Stephan, et al.
Publicado: (2019)

Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity
por: Schweizer, Júnia R O L, et al.
Publicado: (2021)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

Addisonian Crisis after Missed Diagnosis of Posttraumatic Hypopituitarism
por: Streetz-van der Werf, Christine, et al.
Publicado: (2015)

RF13 | PMON159 Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly: MPOWERED Trial Open-Label Extension Phase
por: Fleseriu, Maria, et al.
Publicado: (2022)

One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2021)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

Recent advances in the management of acromegaly
por: Ntali, Georgia, et al.
Publicado: (2015)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

The Development of Neuroendocrine Disturbances over Time: Longitudinal Findings in Patients after Traumatic Brain Injury and Subarachnoid Hemorrhage
por: Kopczak, Anna, et al.
Publicado: (2015)

EZH2 is highly expressed in pituitary adenomas and associated with proliferation
por: Schult, David, et al.
Publicado: (2015)

Sleep quality and health-related quality of life among long-term survivors of (non-) Hodgkin lymphoma in Germany
por: Hammersen, Friederike, et al.
Publicado: (2017)

EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10‐ablation
por: You, Chao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0rojm11hckil3tc099bmt4nhjc